This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.

Indapamide treatment for heart failure - a pilot study

  • Research type

    Research Study

  • Full title

    Treatment of heart failure using indapamide : a pilot study of its effect on plasma FGF23

  • IRAS ID

    213455

  • Contact name

    Leong L Ng

  • Contact email

    lln1@le.ac.uk

  • Sponsor organisation

    University of Leicester

  • Duration of Study in the UK

    1 years, 6 months, 1 days

  • Research summary

    Heart failure patients can have reduced or normal heart muscle contraction. Whilst treatments for reduced contraction have been developed, there are few treatments for patients with normal muscle contraction. Such patients are often older females with high blood pressure who often have stiff hearts. We have found patients with heart failure often have high levels of one particular growth factor (fibroblast growth factor 23, FGF23) that causes heart muscle thickening. We wish to test a drug that is used to treat high blood pressure (indapamide) in patients with heart failure, to see if it affects the blood levels of factors that influence heart muscle thickening. This is a pilot study, involving giving heart failure patients indapamide, and observing the levels of the blood factors over 8 weeks. Patients will be attending on 4 occasions for blood and urine tests. If the pilot study indicates that indapamide could reduce these factors in blood, this would inform a much larger study using both indapamide and a placebo to assess it's effects on heart function.

  • REC name

    East Midlands - Nottingham 1 Research Ethics Committee

  • REC reference

    16/EM/0500

  • Date of REC Opinion

    28 Dec 2016

  • REC opinion

    Favourable Opinion